| Recruiting | Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective NCT07358910 | Institut Pasteur du Cambodge | — |
| Not Yet Recruiting | Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-b NCT06859619 | University Hospital, Montpellier | N/A |
| Terminated | Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults NCT06124144 | University Hospital Tuebingen | Phase 1 |
| Recruiting | Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers NCT06307171 | IRCCS Sacro Cuore Don Calabria di Negrar | N/A |
| Completed | Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan NCT05449717 | Epicentre | — |
| Completed | A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies NCT04512742 | University of York | N/A |
| Completed | Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants NCT04504435 | GlaxoSmithKline | Phase 1 |
| Active Not Recruiting | Mediterranean Visceral Leishmaniasis With Leishmania Infantum NCT03784248 | Centre Hospitalier Universitaire de Nice | — |
| Completed | Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART NCT03993093 | Singh, Ranjan Kumar, M.D. | — |
| Terminated | Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects NCT03874234 | GlaxoSmithKline | Phase 1 |
| Completed | Defining Skin Immunity of a Bite of Key Insect Vectors in Humans NCT03641339 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Completed | Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis NCT02656797 | Soroka University Medical Center | Phase 2 |
| Active Not Recruiting | The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Tri NCT02530697 | University of Brasilia | Phase 2 |
| Withdrawn | Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry NCT02429505 | Knight Therapeutics (USA) Inc | — |
| Completed | Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis NCT03294161 | Hospital Universitário Professor Edgard Santos | Phase 2 |
| Unknown | Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis. NCT03009422 | Tel-Aviv Sourasky Medical Center | N/A |
| Completed | LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine NCT01751048 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers NCT01484548 | Access to Advanced Health Institute (AAHI) | Phase 1 |
| Completed | Intralesional Antimony for Bolivian Cutaneous Leishmaniasis NCT01300975 | Fundacion Nacional de Dermatologia | Phase 2 |
| Completed | Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis NCT01377974 | Brasilia University Hospital | Phase 2 |
| Completed | Th1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes NCT00401297 | Yale University | — |
| Completed | Expression of Mif Alleles in Individuals With Leishmaniasis NCT00401349 | Yale University | — |
| Completed | Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection NCT00401557 | Yale University | — |
| Completed | Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis NCT00373568 | AB Foundation | Phase 1 / Phase 2 |
| Completed | Use of Sodium Stibogluconate as a Treatment for Leishmaniasis NCT00657618 | U.S. Army Medical Research and Development Command | Phase 1 / Phase 2 |
| Completed | Miltefosine for Mucosal Leishmaniasis NCT00373776 | AB Foundation | Phase 1 / Phase 2 |
| Completed | Sodium Stibogluconate Treatment of Leishmaniasis NCT00662012 | U.S. Army Medical Research and Development Command | Phase 2 |
| Recruiting | Diagnosis and Treatment of Leishmania Infections NCT00344188 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil NCT00004755 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Clinical Investigation of Infections Due to Leishmanial Parasites NCT00001169 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Withdrawn | SCH708980 With and Without AmBisome for Visceral Leishmaniasis NCT01437020 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |